



HAL
open science

Applications of Probiotic Bacteria and Dairy Foods in Health

Fillipe Luiz Rosa Do Carmo, Houem Rabah, Bárbara Fernandes Cordeiro, Sara Heloisa da Silva, Gwénaél Jan, Vasco A Azevedo, Rodrigo Dias de Oliveira Carvalho

► **To cite this version:**

Fillipe Luiz Rosa Do Carmo, Houem Rabah, Bárbara Fernandes Cordeiro, Sara Heloisa da Silva, Gwénaél Jan, et al.. Applications of Probiotic Bacteria and Dairy Foods in Health. Current Research in Microbiology, Open Access eBooks 919 North Market Street Suite 425 Wilmington, DE 19801, 2017. hal-01583804

HAL Id: hal-01583804

<https://hal.science/hal-01583804>

Submitted on 7 Sep 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - ShareAlike 4.0 International License

Current Research in Microbiology

Chapter 1

Applications of Probiotic Bacteria and Dairy Foods in Health

Fillipe Luiz Rosa do Carmo^{1,2}; Houem Rabah^{2,3}; Bárbara Fernandes Cordeiro¹; Sara Heloisa Da Silva¹; Gwénaél Jan²; Vasco Azevedo^{1}; Rodrigo Dias de Oliveira Carvalho¹*

¹ UFMG, Federal University of Minas Gerais, 31270-901, Belo Horizonte, Minas Gerais, Brazil

² STLO, INRA, Agrocampus Ouest, 35000, Rennes, France

³ Pôle Agronomique Ouest, F-35042, Rennes, France

*Correspondence to: Vasco Azevedo, UFMG - Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Belo Horizonte - Minas Gerais, Brazil - 31.270-901

Tel.: +55 31 34092610; Fax: +55 31 34092614; Email: vascoariston@gmail.com

Abstract

The intestinal microbiota composition has a great impact on physiology and health, since commensal bacteria are crucial to maintain homeostasis and immune regulation of the gut. Consequently, disturbances of this microbiota, a process known as dysbiosis, have severe implications for the host health such as the rise of many gastrointestinal (GI) problems; including inflammatory disorders like the Inflammatory Bowel Diseases (IBD), mucositis, as well as colorectal cancer (CRC). The consumption of probiotics with beneficial effects is a promising tool to help treating such disorders. Indeed, they modulate diverse biological mechanisms involved in GI homeostasis and have been commonly used to reduce such disorders. In this chapter, we present the molecular mechanisms triggered by probiotic bacteria to modulate the gut physiology during gastrointestinal disorder and the importance of the gastrointestinal stresses tolerance as a limiting factors for probiotic application. Moreover, we focus on the emergence of functional probiotic foods, which can act as excellent vehicles, by enhancing stress tolerance and providing a protective matrix towards digestive stresses.

1. Introduction

Bacteria-host cross talk within the gut is a growing field of interest. While significant-knowledge has been achieved by studies of interactions between pathogenic bacteria and the host, much research is required for understanding the impact of commensal bacteria that reside

within the human gastrointestinal tract (GIT) [1]. An increasing number of studies indicate that the intestinal microbiota is essential for host functions, especially immune responses that contributes to gut homeostasis [2-5]. More recently, several studies show correlations between disturbed microbiota composition (dysbiosis) and diseases which involve gastrointestinal inflammation [6-9]. Individuals presenting these inflammatory conditions are colonized by an abnormal microbiota and it has been revealed that the lack of bacteria involved in regulation of the gut immune system might be a key factor in the chronicity of mucosal inflammation [10,11]. Therefore, a novel rationale aiming at the restoration of a healthy microbiota has been glimpsed by researchers to prevent and/or help in treating gastrointestinal diseases. In this context, there has been much encouragement for the use of probiotics and functional foods as therapies for such disorders. In this chapter, we describe the most recent advances of dairy foods and probiotic strains protective effects in animal models of intestinal inflammation and in human clinical trials. Furthermore, the challenges and limitations in regard of stability and safety of these approaches are discussed.

2. Gastrointestinal Tract

2.1. Microbiota

The GIT of mammals is a complex biological system whose main function is the digestion of food. As the GIT is an environment that is very rich in nutrients, particularly the ileum and colon parts, there is a dynamic community of microorganisms, known as intestinal microbiota, which plays a role in the intestinal physiology and immune regulation [12-14].

The community of bacteria found in the GIT contains both indigenous and transient members. The first ones are well adapted to the intestinal environment and thus colonize the lumen. In turn, the transient microorganisms are not able to survive more than a few days. Some transient species are frequently ingested in substantial amounts as they are present in fermented dairy foods such as yogurts, cheeses and fermented milk. However, transiting bacteria also include several of the enteric food-borne pathogens [15,16]. The survival of allochthonous bacteria in the GIT depends on several factors including the ability to tolerate gastric acid, bile salts and pancreatic juice [17].

Many academic and industrial consortiums, such as the MetaHIT (Metagenomics of the Human Intestinal Tract), have attempted to characterize the microbiota associated with the human GIT through genomic sequencing, thus giving a more detailed description of the human intestinal microbiota composition and of its function [18,19]. It is estimated that the intestinal microbiota comprises 500 to 1,000 species of bacteria, exceeding 10 times or more the total number of host cells [7,20,21]. Nowadays, it is known that most species found in mammalian GIT can be classified into four phyla: Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria [21-23]. These phyla keep symbiotic relationships with the host, making

fundamental contributions to the host metabolism while occupying a protected environment rich in nutrients [24,25]. In this context, the intestinal microbiota plays major roles such as nutritional functions, prevention of pathogen colonization, trophic functions on the proliferation and differentiation of the intestinal epithelium, and development and modulation of the host immune system [21,26-9].

Although the microbiome composition varies greatly among individuals, its composition is relatively simple during the first years of life. It has been reported that *Escherichia coli* and streptococci are the most common organisms isolated from the upper GIT shortly after birth [21,30]. These species are responsible for creating a favorable environment, promoting in turn the colonization by anaerobic bacteria, among which *Bifidobacterium* and Bacteroidetes are most prevalent. The *Bifidobacterium* genus plays an important role in the intestines, as these bacteria can down-regulate the expression of key proinflammatory mediators in the gut and inhibit pathogens. Bacteroidetes species have great capability to digest complex sugars, and thus maintain stable symbiotic relationship with the host and central position in the gut microbiome [31-34]. Afterwards, in the course of life, there can be an increase of Firmicutes, especially of the Lactobacillales and Clostridiales Orders. Among these, several members, including remarkably *Faecalibacterium prausnitzii*, are Short Chain Fatty Acid-producers, SCFAs playing an important role on the maturation of regulatory T cells [35]. Although microbiota is stable in older persons, it can be altered in short term duration by dietary intervention [36]. Dietary intake shifts, mainly of dairy foods containing *Lactococcus* sp or *Propionibacterium* sp and non digestible carbohydrates, may change the composition of the gut microbiota by increasing the number of *Bifidobacterium* sp and *F. prausnitzii*, although these bacteria do not respond in the same way in all human subjects [27,37,38].

In adulthood, the diversity and abundance of bacterial populations vary along the different parts of GIT [13,21,39,40]. In the stomach and duodenum, a small number of microorganisms can be found, while up to 10^3 bacterial cells are present per gram of duodenal content. These bacteria are adhered to the mucosal surface or in transit through the GIT [26,41,42]. Streptococci and lactobacilli are among the most common groups of bacteria found in this part of the intestine [39,43-45]. The bacterial population increases gradually along the jejunum and the ileum, reaching numbers around 10^4 - 10^7 per gram of small intestinal content. However, it is in the lower GIT (colon) that the highest density of bacteria population is encountered, reaching a number of 10^{11} - 10^{12} per gram, making this area one of the most complex microbial ecosystems known to date on Earth [13,45].

2.2. Immune system regulation

Commensal species from the intestinal microbiota are not ignored by the immune system but on the contrary need to be recognized by mammalian cells to deliver tolerogenic sig-

nals and promote intestinal immune homeostasis with an impact on the immune system of the body. Actually, commensal bacteria and their host have co-evolved diverse biological mechanisms making this cross talk possible [46]. For example, pattern recognition receptors (PRRs), especially Toll-like receptors (TLRs), expressed by Intestinal Epithelial Cells (IECs), are able to recognize microbe-associated molecular patterns (MAMP) of the commensal microbiota. In fact, the expression of PRR and their interaction with the microbiota is very important for the healthy development of the host immune system [47-49].

These MAMP are microbial components, such as lipoproteins, nucleic acids (RNA and unmethylated CpG dinucleotides), lipopeptides, lipopolysaccharide (LPS), surface proteins such as flagellin and peptidoglycan [7,50-52]. The recognition of a MAMP transduces signals that subsequently activates innate immune responses [50,52].

Species from Lactobacillales order and the Actinobacteria phylum (*Bifidobacterium* sp. and *Propionibacterium* sp.) [30,53] are capable of stimulating luminal secretion of antimicrobial peptides by Paneth cells, mucins by goblet cells and fortifying tight junctions of IECs [54, 55]. Furthermore, commensals are reported to induce signals of immunological tolerance, such as secretion of the TGF- β cytokine that inhibits the NF- κ B signaling pathway inside epithelial cells. It has been shown that activation of TLRs by commensal bacteria also promotes the development of CD103 dendritic cells, which are responsible for driving the activation of Treg cells [56-58]. It is known that Treg cells suppress effector T cell responses mainly through the production of IL-10 and TGF- β . The stimulation of these cytokines prevents the recruitment of granulocytes, suppressing the activation of macrophages, neutrophils and endothelial cells. In addition, Treg cells expressing TGF- β and IL-10 drive B cells to undergo antibody class switching to produce IgA antibody, the major humoral defense of mucosal surfaces. Secretory IgA (sIgA) contributes to mucosal homeostasis through a process known as immune exclusion. sIgA is able to bind to opportunistic pathogens avoiding its dissemination throughout the body [59-61].

Although commensal microorganisms show beneficial effects on the host, some microbes of the GIT might present potential risk if case of outgrowth. In this context, potentially pathogenic species, known as pathobionts, composed mainly of Proteobacteria members, such as *Escherichia coli*, and species from the phylum Firmicutes, as *Clostridium difficile* and *Enterococcus faecalis* can elicit a pro-inflammatory immune response after binding to TLR [47, 53,62].

When pathobionts translocate to intestinal epithelium, the host immunity is activated and is usually enough to eliminate the intruder. Nonetheless, the overproduction of pro-inflammatory cytokines, which may occur during dysbiosis, represents a risk once inflammation may also be problematic causing cell disruption and infection to the host. Therefore, to reach intes-

tinal homeostasis, the gut immune system must be able to recognize and eliminate specifically these pathobionts from the GIT [54,63]. Intestinal barrier dysfunction generates an imbalance between immune responses observed for protective and harmful intestinal bacteria and thus contributes to the onset of several inflammatory conditions of the GIT [7,64].

2.3. Inflammatory disorders

The GIT is permanently challenged by antigens from the intestinal microbiota. Under normal conditions, the intestinal mucosa maintains tolerance to commensals, mainly through the action of Treg cells. When the dynamic balance between Treg and activated effector cells is broken, the homeostasis is compromised and this may lead to the development of mucosal inflammation [2]. Besides dysbiosis, multiple factors can influence the proper functioning of the GIT immune system, including individual genetic background, diet, use of drugs and environmental stress. The intersection of these factors generates an exaggerated pro-inflammatory reaction against commensal antigens leading to Inflammatory Bowel Diseases (IBD), a group of chronic inflammatory conditions of the GIT, which primarily includes ulcerative colitis (UC), and Crohn's disease (CD) [21,30]. Clinical symptoms of both diseases are similarly found in patients, such as abdominal pain, diarrhea, rectal bleeding and weight loss [65,66]. Relapse symptoms can last days, weeks, or even months [67]. CD is characteristically discontinuous, with inflamed areas that can be found in all the layers of the intestinal wall, while UC is characterized as a continuous and superficial inflammation limited to the colon [68,69]. The incidence of these diseases varies widely across countries, however, in recent years, it has increased considerably worldwide, being considered a global public health problem. This increase has been associated with the modern lifestyle that includes the ingestion of processed foods usually high in fats and sugar and low in fiber [70-72].

Caesarean delivery and the inappropriate use of antibiotics, especially during childhood, when the microbiota has not yet been established, are factors that can contribute to the development of intestinal inflammation [30,72-74]. Both CD and UC have different immunological aspects when it comes to innate and adaptive immunity [75,76]. Pro-inflammatory cytokines are over expressed in IBD patients; however, the predominant set of cytokines observed in CD patients is the one secreted by Th1 and Th17 cells (IL-12, IL-23, IL-27, IFN- γ) whereas in UC patients a Th2 immune response, characterized by the production of IL-4 and IL-13, appears to be predominant [3,4,74].

Chronic inflammation also plays a role in the pathogenesis in several cancers and it has been shown that there is a direct link between IBD and colorectal cancer (CRC) [77]. Individuals suffering from long-term ulcerative colitis or Crohn's disease have increased risk of developing CRC [78].

Reactive Oxygen Species (ROS), stimulated by proinflammatory response in the intes-

tinal mucosa, play an important role in the development of CRC, as their excessive levels can result in oxidative stress and significant damage to cell structures and macromolecular constituents, such as DNA, RNA, proteins and lipids [79,80]. Large amounts of hydrogen peroxide (H_2O_2) are produced and excreted by human tumor cells, and might participate in tumor invasion and proliferation as well [78,81]. Furthermore, current studies are investigating the role of effector immune responses against intestinal microbiota in modulating the gut microbiota into a carcinogenic profile composition. In fact, a correlation between diet-driven sulfidogenic bacteria and CRC in African Americans has been demonstrated [82,83].

Other factors such as the use of some medicines can also contribute to the breakdown of this immunological tolerance against commensals commonly observed under normal conditions. It has been described that chemotherapeutic agents, as 5-Fluoracil (5-FU), doxorubicin and irinotecan (CPT-11), widely used in the treatment of advanced solid tumors, may also lead to the development of another inflammatory condition of the GIT, known as mucositis. This painful inflammation of the mucosa can affect all portions of the human GIT and has great medical importance as it arises as an adverse effect of chemotherapy [84,85]. These medicines are effective in cancer treatment because they inhibit cell proliferation. 5-FU, for example, causes cytotoxic effect by inhibiting DNA replication in cells with a high mitotic index such as malignant cells. Moreover, this drug can also be incorporated into RNA molecules interfering with their processing and function. However, as an adverse consequence, the drug also shows an effect in normal cells that presents a higher turnover rate, such as GIT enterocytes [86]. Gastrointestinal mucositis is being regarded as a major risk, occurring in 80% of patients receiving 5-FU [87,88].

Patients with mucositis develop symptoms like odynophagia (pain in swallowing), vomiting, abdominal pain and diarrhea, which make eating difficult. Therefore, weight loss and malnutrition are also reported and quality of patient's life is. Gastrointestinal mucositis is characterized by morphological alterations in the mucosal architecture, as villous atrophy, increased crypt apoptosis, that expose the mucosa to intestinal pathogens, which are able to translocate across intestinal epithelial cells leading to inflammatory responses [89].

The pathophysiology process of mucositis is very complex and involves the release of endogenous damage-associated molecular pattern (DAMP) molecules and activation of the NF- κ B pathway, which induces in turn the expression of several genes, including pro-apoptotic enzymes such as caspases, tumor necrosis factor-alpha (TNF- α), IL1- β and IL-6 cytokines, and chemokines involved in the recruitment of neutrophils and eosinophils. Commensal bacteria might have a very important role in promoting many clinical aspects involved in the pathogenesis of mucositis [90-94], as it was demonstrated that germ-free mice are more resistant to mucositis induction [85,95]. Moreover, opportunistic species belonging to the gut microbiota, such as *Enterococcus faecalis*, *Escherichia* sp and *Clostridium* sp can alter intestinal

permeability during anticancer treatments and promote disruption of the epithelial layer. The translocation of commensals across IEC exacerbates inflammatory responses and amplifies the damage to the intestinal mucosa [92,95].

As alterations of the intestinal microbiota have been implicated in all of these pathologies, the scientific community has been investigating the use of probiotics in order to restore the original gut microbiota, which is responsible for regulating the mucosal immune system.

3. Probiotics

The administration of probiotics for treating gastrointestinal inflammatory disorders have been proposed by many research groups, as they are able to occupy niches that compete with pathogens in the GIT [96-101]. Probiotics are defined as “live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host” [102]. These microorganisms must be safe and present beneficial effects during their transit through the gut. Hence, their ability to resist the stomach and intestine environments are crucial alongwith the capacity of adhesion to intestinal cells, inhibition of pathogens and immunomodulatory effects [103]. Currently, several species of probiotic bacteria are used to prevent or treat a diversity of diseases, including gastrointestinal inflammatory disorders (**Table 1**). Lactobacilli and bifidobacteria, for a long time, were at the front of the stage in the field of this probiotic action. However, outsider bacterial species such as *Lactococcus lactis*, *Streptococcus thermophilus*, *Escherichia coli* and *Propionibacterium freudenreichii* recently revealed promising potential for the treatment of intestinal inflammation as well [104-107]. This is summarized in section 4.

Table 1: Immunomodulatory effects of probiotics in experimental animal model

Probiotic species	Model system	Probiotic effect(s)	Mechanisms involved	Reference(s)
<i>Escherichia coli</i> M17	DSS	Attenuates colitis	Inhibits NF- κ B, decreases colonic IL- 12, IL-6, IL1- β and IFN- γ	(FITZPATRICK et al., 2008) (108)
<i>Lactobacillus casei</i>	TLR4 KO and DSS	Attenuates colitis	Reduces proinflammatory cytokines secretion and neutrophil recruitment	(CHUNG et al., 2008) (109)
<i>Faecalibacterium- prausnitzii</i>	TNBS	Attenuates colitis	Increases colonic IL10 and decreases colonic IL12. Tends to correct the dysbiosis associated with TNBS colitis	(SOKOL et al., 2008) (110)
Mix of four <i>lactobacillus</i> or four <i>Bifidobacterium species</i>	DSS	Attenuates colitis	Reduces colonic proinflammatory cytokines	(NANDA KUMAR et al., 2008) (111)
VSL#3	TNBS	Attenuates colitis	Increases production of IL-10 and Tregs	(DI GIACINTO et al., 2005) (112)

<i>Lactobacillus salivarius</i> Ls33	TNBS	Attenuates colitis	Increases IL-10 production and Tregs	(MACHO FER-NANDEZ et al., 2011) (113)
<i>Lactobacillus plantarum</i> DSM 15313, <i>Lactobacillus fermentum</i> 35D	DSS	Attenuates colitis	Reduces bacterial translocation	(OSMAN et al., 2008) (114)
<i>Bacteroides fragilis</i>	TNBS	Attenuates colitis	Increases production of IL-10 and Tregs	(ROUND and MAZMANIAN, 2010) (115)
<i>Lactobacillus salivarius</i> 433118, <i>Bifidobacterium infantis</i>	IL-10 KO	Attenuates colitis	Reduces inflammatory cytokines	(MCCARTHY et al., 2003) (116)
<i>Lactobacillus casei</i> Shirota	DSS	Attenuates colitis	Reduces IL-6 production by lamina propria mononuclear cells	(MATSUMOTO et al., 2005)(117)
<i>Enterococcus faecium</i> CRL 183	1,2 dimethylhydrazine (DMH)	Reduces ACF and adenocarcinomas incidence	Improved the immune response by increasing IL-4, IFN- γ , and TNF- α production	(SIVIEIRI et al., 2008)(118)
<i>Saccharomyces boulardii</i>	C57BL/6J Min/+ (Apc-Min) mice (7 wk old).	Reduces number and diameter of the tumors, the score for low-grade dysplasia, numbers of polyps, and cell proliferation	Inactivation of the EGFR-Mek-Erk pathway signaling. Increase apoptosis	(CHEN et al., 2009)(119)
<i>Lactobacillus acidophilus</i> NCFM	CT-26 cells	Reduces tumor size and the extraintestinal metastatic tissue	Increase apoptosis through increase caspase-9 and caspase-3 and reduces Bcl-2 expression	(CHEN et al., 2012) (88)
<i>Lactobacillus plantarum</i> AdF10 and <i>Lactobacillus rhamnosus</i> GG	1,2 dimethylhydrazine (DMH)	Reduces tumor incidence, multiplicity, and size	Reduces COX-2 protein expression	(WALIA et al., 2015) (120)
<i>Lactobacillus salivarius</i> Ren	1,2 dimethylhydrazine (DMH)	Reduces tumor incidence	Reduces Intestinal population of Ruminococcus sp and Clostridiales bacteria \uparrow Intestinal population of Prevotellasp	(ZHANG et al., 2015) (121)
Dead nanosized <i>Lactobacillus plantarum</i>	Azoxymethane/ Dextran Sulfate Sodium-Induced	Reduces tumor incidence; areas of dysplasia, adenocarcinoma, and structural disruption	Reduces Over expression of proinflammatory cytokines and inflammatory genes Increase Apoptosis and cell cycle arrest	(LEE et al., 2015) (122)
<i>Lactobacillus rhamnosus</i> and <i>Lactobacillus acidophilus</i>	1,2 dimethylhydrazine (DMH)	Reduces tumor incidence, burden and multiplicity; lipid peroxidation	Reduces GSH, SOD, and GPx activity	(VERMA and SHUKLA 2014) (123)

<i>Lactobacillus casei</i> BL23	1,2 dimethylhydrazine (DMH)	Reduces colorectal cancer	Regulates Treg and Th17 T-cell populations	(LENOIR et al., 2016) (124)
<i>Pediococcus pentosaceus</i> GS4	Azoxymethane	Attenuates colon cancer	Triggered apoptosis in colonocytes	(DUBEY et al., 2016) (125)

3.1. Bacteria for the treatment of gastrointestinal disorders

Many strains of bacteria are known to exert anti-inflammatory effects through the modulation of factors that are involved in maintaining intestinal homeostasis in humans and other animals [97,101]. In this context, bacterial effectors of distinct nature have been implicated in probiotic effects. These include metabolites, peptidoglycan, surface proteins, lipoproteins and lipoteichoic acids, lipopolysaccharides, flagelin and CpG motifs in DNA. Some of these molecules, such as anti-microbial peptides and prebiotic metabolites may interact directly with other species of bacteria that colonize the gut, modulating their growth. Others bacterial factors, called MAMP, bind to PRRs of eukaryotic cells and stimulate different patterns of gene expression in the host involved in innate immunity activation and differentiation of antigen-specific immunity [53,126]. The mechanism of action of these bacteria can be classified in three main categories: alteration of gut microbiome composition, stimulation of epithelial barrier function; and induction of the immune responses [127].

Recent advances in genomic sequencing technologies have provided the scientific community with tools to explore the human microbiome and how different treatments affect its global composition and function. Several studies have shown that probiotics can increase or decrease the abundance and diversity in gut microbial species composition. The secretion of antimicrobial compounds acts by directly inhibiting the growth of pathogens. In addition, probiotic strains may also reduce the impact of pathogens through a mechanism known as competitive exclusion, in which they occupy binding sites at the mucosal surface [97,128,129].

Epithelial barrier function enhancement is a well-established mechanism of probiotic bacteria in the protection of the host against invasive harmful bacteria. Numerous studies have shown that probiotics have the potential to modulate many of the processes involved in mucosal barrier formation and are able to upregulate expression of defensins, mucins or proteins associated with tight junctions such as claudins and occludins [130-132]. This effect is therefore considered as one of most important for the prevention and treatment of IBD and mucositis, as it might avoid translocation of opportunistic pathogens to systemic circulation [84,101].

Probiotics can affect the host health by modulating inflammatory signaling pathways. Several probiotics are reported to inhibit the NF- κ B activation and thus to influence downstream cytokine secretion [133]. Recent studies demonstrated that the anti-inflammatory effects of some bacteria involve inhibition of I κ B degradation by targeting the different steps involved

in this process which are phosphorylation, ubiquitination or proteasome degradation [134]. Some Lactobacilli have shown inhibitory activity of TNF- α induced secretion of IL-8 [135]. Other well established immunological mechanism of probiotics is the stimulation of immunological tolerance to GIT microbiota through the increase in IL-10 secretion. For instance, Santos and collaborators (2014) showed that the probiotic effect of *L. delbrueckii* strain CNRZ327 was related to an expansion of Treg cells and an increase of total IgA in Dextran sulfate sodium (DSS)-induced colitis in mice. Recently, it was reported that a *Lactococcus lactis* sp. *lactis* NCDO2118 strain prevented DSS-induced colitis in mice and the protective effect was related to increased IL-10 levels in the colon and to the induction of Treg cells in the mesenteric lymph nodes [99].

Most studies focused on the beneficial effects autochthonous Lactobacilli (**Table 1**). However, recent studies have demonstrated that some allochthonous strains have anti-inflammatory properties. Ballal and colleagues (2015) found that *L. lactis* I-1631 prevents colitis in T-bet $^{-/-}$ Rag2 $^{-/-}$ mice. Two additional studies have shown that, among the *L. lactis* species, NCDO2118 subsp. *lactis* or FC subsp. *cremoris* are anti-inflammatory when inoculated in inflamed mice receiving the chemical agent DSS [99,136]. Moreover, *L. lactis* NZ9000 by itself was able to prevent histological damage and reduce neutrophil and eosinophil infiltration in mice injected with 5-FU. Another allochthonous species with anti-inflammatory effects in IBD models is *Propionibacterium freudenreichii*, used extensively as a ripening starter of Emmental cheese [104,137,138].

3.2. Challenges and limitations to select probiotic bacteria

For probiotic bacteria selection, the robustness of a bacterium against different abiotic and biotic stresses is crucial, and may constitute a limiting factor for its application as probiotic. Firstly, to prepare probiotic ingredients, a plethora of stresses are applied, thus the bacterial tolerance is a prerequisite for reaching a high survival rate in the product. In the traditional cheese products, the manipulation of bacterial population could be limited by other factors. However, for the probiotic powders, great efforts were made to maintain a high viable bacterial population during freeze-drying or spray drying, such as usage of encapsulation methods. Gastrointestinal stresses also constitute the main bottleneck of probiotic efficacy.

A probiotic microorganism must be able to tolerate digestive stresses and to adhere to intestinal epithelium, for a long persistence in the host and for an enhanced beneficial effect. Gastric acid and bile salts are defense mechanisms encountered during intestinal transit whereas pancreatic secretions can also exert some antimicrobial activity via the digestive enzymes. The existing microbiota may also interfere with the probiotic effect by competition for adhesion or nutrients. The investigation of molecular basis of the adaptive response to stresses and identification of the pivotal genes involved provided pertinent tools for probiotic screening.

3.2.1. Acid stress

The probiotic resistance to acid stress is a desired characteristic of selected strains, as low pH is widely encountered both during technological processing and during gastric digestion. The bacterial adaptive responses to acid challenge have been investigated and some of the molecular mechanisms involved were elucidated, such as induction of proton ATP-dependent pumps F_1F_0 -ATPase. The function of this transmembrane protein complex is the extrusion of protons from the cell cytoplasm, resulting in a Proton Motive Force (PMF), and avoiding acid-stress induced drop in intracellular pH [139]. Mutations leading to a reduction of membrane-bound ATPase activity were observed in some strains of *Lactococcus lactis* subsp. *lactis* and *Lactobacillus helveticus*, where they cause growth inhibition under acid conditions [140,141]. Gram-positive bacteria, such as *Lactococcus lactis* [142] and *Lactobacillus brevis* [143], possess a second mechanism for an adaptive response to acid stress, involving the enzyme glutamate decarboxylase (GAD). The GAD system imports glutamate into the cell prior to its decarboxylation, which consumes protons, participating in intracellular pH homeostasis, followed by the efflux of the resulting γ -aminobutyrate (GABA), thanks to a GAD/GABA antiporter. Another mechanism involved in pH homeostasis is the proton-consuming malolactic fermentation (MLF). This metabolic pathway leads to the conversion of the dicarboxylic malic acid to the monocarboxylic lactic acid. The latter is excreted via a lactate-malate antiporter, resulting in intracellular alkalinization. Such mechanism was observed within several bacteria like *Lactobacillus sakei* [144], *Lactobacillus plantarum* [145], and *Lactococcus lactis* [146]. Finally, other acid-adaptive mechanisms induced in lactic acid bacteria include the citrate-lactate antiporter (CitP), the arginine deiminase (ADI) system and some heat shock [147-149].

3.2.2. Bile salts

Conjugated bile salts are synthesized by the liver with the amino acids glycine or taurine, those amphipathic molecules act like biological detergents with strong antimicrobial activity cause can emulsify biological membrane lipids [150,151]. These compounds may enter into the bacterial cytoplasm by flip-flop mechanism and cause oxidative stress which leads to DNA damage [152-154]. In fact, there are different remarkable mechanisms leading to bile salts tolerance; those molecular actors can also provide bacteria a cross protection towards other stress types. Some probiotic bacteria hold the ability to hydrolyze bile salts by bile salt hydrolases (BSHs) which enhances their survival in the digestive tract [155]. Alternative mechanisms exist such as bile-efflux systems, which are multidrug transporters that mediate the active extrusion of bile salts from the bacterial cytoplasm [156]. Regarding *Lactobacillus acidophilus* particularly, an eight-gene operon encoding for, a two-component regulatory system, a transporter belonging to the major facilitator super family, an oxido reductase, and four hypothetical proteins, has been implicated in bile salts removal [157].

3.2.3. Heat stress

Heat stress is another type of ordeal that is commonly suffered during technological processes, either during food fermentation (cheese cooking-step) or during drying, which may impose high temperatures ($>60^{\circ}\text{C}$) or low temperatures, depending on the chosen technology. The response to heat stress involves a set of proteins called Heat Shock Proteins (HSP), which include chaperones and proteases. They are essential for overcoming protein denaturation, maintaining cell homeostasis in response to variations of temperature, which can affect membrane fluidity and compromise cellular integrity and basic cell processes [158,159]. Among those crucial proteins, DnaK and GroEL, are two HSPs that have a critical role in cellular processes by maintaining DNA replication process, preventing mutagenesis and preventing protein denaturation [158,160]. Otherwise, low temperatures are frequently used to prevent spoilage during frozen and freeze-dried storing process. Such a cold stress leads to induction of specific proteins called cold shock proteins (CSPs). Their role consists in maintaining transcription and translation processes under cold stress adaptation [159].

3.3. Protective matrix and vectorization

Although the adaptive response to various stresses is a quite important feature to screen tolerant or sensitive probiotic strains, vehicle matrix can confer a protection for an efficient delivery of probiotic bacteria to the GIT. Probiotics are commonly consumed under the form of dried powder, in capsules or tablets. Recently, various studies focused on “2-in-1” starter bacteria: microorganisms widely used in food fermentation and which exert beneficial effects. There is a huge variety of fermentative microorganisms known for their probiotic properties like *S. thermophilus*, *L. delbrueckii* ssp. *bulgaricus*, *L. lactis*, and other strains used for specific fermented foods [161]. The growth in such stressful medium as dairy fermented foods selects bacteria with a high robustness to GIT stresses there by promoting long-term survival during storage in industrial process.

3.3.1. Encapsulation by biopolymers

Encapsulation is a standard process used to produce protected dried probiotic ingredients. Encapsulation may confer a protection against industrial stresses during the drying process, and allow a controlled release in the GIT [162,163]. Depending on the type of drying technology (capsule spray-drying, emulsification, extrusion, co-extrusion, or spray-coating), different particles sizes may be obtained and interfere in the encapsulation yield. Moreover, semi-permeable and biocompatible matrices including food-grade biopolymers like alginate, pectin and cellulose acetate phthalate are used for preventing oxidative reaction, masking flavor and odor changes. The encapsulation essentially provides a protection for bacteria and a specific addressing of active probiotic compounds to specific sites [164,165]. Among polymers used for encapsulation; alginate, a polysaccharide composed of β -D-mannuronic and

α -L-guluronic acids, is widely used, because of its simplicity, biocompatibility, low cost, and non-toxicity. Recently, the encapsulation by alginate was shown to confer enhanced viability upon storage and simulated gastrointestinal digestion for *Lactococcus lactis* subsp. *cremoris* LM0230, *Lactobacillus casei* NCDC 298, *Bifidobacterium longum* and other probiotics [166-168].

3.3.2. Encapsulation by milk proteins

The utilization of milk proteins for probiotic encapsulation is a high quality choice due to their biocompatibility, structural and physico-chemical properties [169]. Milk proteins are categorized in two types: caseins and whey proteins. Caseins are a complex aggregate of phosphoproteins and are extremely heat-stable proteins, present in colloidal form known as caseins micelles in fresh milk [170]. Whey proteins are a group of globular proteins, α -lactalbumin, β -lactoglobulin, immunoglobulins, and serum albumin and also various other minor proteins [171]. Milk proteins clotting followed by spray-drying appears as new innovative methodology to encapsulate probiotic bacteria to enhance survival in GIT [172]. Heidebach *et al.* in 2009 demonstrated new methodologies based on a transglutaminase-catalyzed gelation of casein suspensions and spray drying to encapsulate *Lactobacillus paracei* ssp. *paracasei* F19 and *Bifidobacterium lactis* Bb12. It was shown to enhance robustness in stressing conditions [173,174].

3.3.3. Dairy Fermented foods

The emergence of functional foods concept such as fermented products is a promising research area. Indeed, the dairy fermented foods constitute an important part of our daily diet [175], as well as our main microbial daily intake. The dairy product matrix may increase tolerance of bacteria towards digestive stresses and adhesion to cells, depending on its biochemical composition, its physical microstructure and the existing microbial ecosystem, which affects directly the viable bacterial amount reaching the gut. Beyond the protection effect of the vehicle matrix, fermentation allows improvement of food nutritional value through the microbial release of a high amount of essential nutrient for consumers [176], including vitamins.

Probiotic bacteria convert different molecules, producing valuable nutrients like conjugated fatty acid, B-galactosidase enzyme, beneficial dairy peptide, which can enhance their probiotic functionality [24,25]. Indeed, *L. casei* BL23 incubated in milk reduced significantly the symptoms of a dextran sulfate sodium (DSS) - induced colitis in a murine model, compared to the same strain provided in phosphate buffered saline [178,179]. Yogurt enhances the therapeutic value of some probiotic bacteria, however the low pH of yogurt decreases viable population [177,180,181]. To contend this problem, a combination of encapsulated probiotic bacteria was used to increase survival in yogurt. For example, *L. paracasei* subsp. *paracasei* E6 were encapsulated using whey proteins and gum arabic, before being added to the yogurt

matrix after fermentation. This bacterium exhibited greater viability, compared to cells without encapsulation, upon exposure of the probiotic yogurt to simulated gastric juice [182,183].

Cheese matrix favors probiotic beneficial effects by providing a favorable environment with relatively high fat content, enhancing probiotic survival in transit through the GIT, especially towards lethal conditions of the stomach [184]. Özer and colleagues showed increased viability of *Bifidobacterium bifidum* BB-12 and of *Lactobacillus acidophilus* LA-5, when these bacteria were microencapsulated in white-brined cheese, compared to same strains without encapsulation protection [185]. Other strains have been used to produce experimental probiotic cheese, including *Lactobacillus casei* and *Lactobacillus acidophilus* in Crescenza cheese. They exhibited improved viability, during the refrigerated storage, after a cheese manufacture using High-pressure homogenization (HPH) as an alternative to traditional thermal treatment [186]. The potential probiotic *P. freudenreichii*, alone or in combination with *Lactobacillus delbrueckii*, was investigated with respect to the prevention of UC. The experimental fermented cheeses exhibited promising anti-inflammatory properties in mice with colitis [187,188]. Moreover, inclusion within a cheese enhanced *P. freudenreichii* tolerance towards digestive stresses and thus its probiotic properties [105].

4. *Propionibacterium Freudenreichii* for Treating Gastrointestinal Disorders

During the last two decades, an outsider, that had until then been ignored, was considered for probiotic applications. The propionibacterium *P. freudenreichii*, until then used almost exclusively to confer aroma to pressed cheeses, joined the main probiotic actors on the stage of probiotic research and development. *P. freudenreichii* indeed recently revealed unexpected immunomodulatory effects. This evidenced for the first time a “two-in-one” property of an ill-known ripening starter, with both technological and probiotic abilities.

4.1. General aspects of *P. freudenreichii*

4.1.1. Taxonomy

P. freudenreichii is a dairy propionibacterium, which belongs to Actinobacteria, characterized as gram-positive with a high G+C content, non-sporing, anaerobic to aerotolerant, non-motile pleomorphic rods [189,190]. Actinobacteria comprise bacterial species with a mycelium-like aspect, found in various environments, including animal hosts and soil [189,190]. The genus *Propionibacterium* comprises both cutaneous species, which may act as opportunistic pathogens, and dairy species, which have no reported adverse effects up to date [191]. The typical dairy species isolated from milk are: *P. freudenreichii*, *P. acidipropionici*, *P. jensenii* and *P. thoenii*; they are clearly distinct from cutaneous species. Dairy propionibacteria were firstly described by E. von Freudenreich and S. Orla-Jensen at the end of 19th century, since their presence in Emmental cheese was associated with propionic fermentation [192]. Dairy

propionibacteria, specifically *P. freudenreichii*, possess a long history of safe use in food, particularly by Swiss-type cheese. *P. freudenreichii* received the “Generally Recognized As Safe” (GRAS) status [193]. The European food safety authority has granted “Qualified presumption of safety” (QPS) status to two species: *P. freudenreichii* and *P. acidipropionici* [194]. The sequencing of *P. freudenreichii* genome revealed the genetic basis of the great adaptation ability to various environments [195]. They moreover display a peculiar fermentative metabolism, which relies on propionic fermentation, may use various carbon and energy sources, and release in the extracellular medium various beneficial metabolites [190,195].

4.2. *P. freudenreichii* technological applications

4.2.1. Swiss-type cheese manufacturing

The major use of *P. freudenreichii* strains is as ripening culture in Swiss-type cheeses manufacturing. They play an important role in characteristic flavor of cheeses such as Emmental cheese [189]. *P. freudenreichii* produces several flavor compounds via different substrates catabolism. lactate and aspartate fermentations generate short fatty acids accumulation, mainly propionic and acetic acids, and to a lesser extent valeric and isovaleric acids. These short fatty acids are considered as principal flavor compounds in Emmental. *P. freudenreichii* also possesses a strain-dependent lipolysis activity, which produces free fatty acids that are important molecules for cheese flavor. The amino acids catabolism by *P. freudenreichii* produces two branched-chain flavor compounds: 2-methylbutanoic acid and isovaleric acid [190]. In Emmental cheeses, *P. freudenreichii* reaches a high population density, with counts depending in ripening period. The *P. freudenreichii* robustness permit a high tolerance to different stresses during cheese manufacturing process, such as high and low temperature, acidification, osmotic stress induced by NaCl [190,196]. In addition, *P. freudenreichii* can also be found in low amount in various cheeses, in addition to Emmental cheese [189].

4.2.2. Anti-microbial & Nutraceutical molecules production

P. freudenreichii is a well-known vitamin B₁₂ producer, actually, the only B₁₂ producingbacteria with the GRAS status [190,197]. Vitamin B₁₂ is an essential vitamin, required for maintaining healthy nerve cells, DNA synthesis and energy, and for other important functions. Vitamin B₁₂ is synthesized industrially by chemical synthesis, which is too difficult and expensive. Many efforts were made to enhance the productivity of vitamin B₁₂, by using genetic engineering and by optimizing fermentation conditions. In addition, *Propionibacterium* spp strains, have preservatives properties and are widely employed to extend foods shelf-life by inhibiting undesirable microorganisms growth. A commercial product is available under Microgard™ name, which is composed of skim milk fermented by *P. freudenreichii* subsp *shermanii* [190,192,197]. The short chain fatty acids propionate and acetate, as well as other organic acids such as succinate, are the main anti-microbial molecules produced by dairy pro-

propionibacteria. However, *P. acidipropionici* species were shown to be the best producer of propionic acid, through glycerol fermentation without acetic acid production [197]. Different bacteriocins that are produced by both dairy and cutaneous propionibacteria, have been reported and characterized [190,192,197]. However, further studies are required to assess their possible use as food biopreservatives or bacteriocin producer probiotics to inhibit intestinal pathogens, as dairy propionibacteria bacteriocins are not still recognized as GRAS by the FDA.

4.3. Probiotic application

Recent data suggest the probiotic potential application of dairy propionibacteria, mainly *P. freudenreichii*, for human and animal, as this species presents all characteristics for probiotic application [192]. Indeed, it shows a high tolerance to digestive stresses, which is one of the main factors limiting the use of microorganisms as live probiotic agent [192]. Propionibacteria species have a slow growth rate, so their adherence to intestinal epithelium is crucial for their persistence in the gut and for exerting their beneficial effects [190,192]. Some studies demonstrated the dairy propionibacteria ability to adhere to intestinal cells, however all those studies are *in vitro* experiments, and the adhesion presented a lot of variations according to adhesion model used, species types, and vehicle or growing medium [192]. *In vivo* studies, in humans and mammals, suggest that this adhesion ability allows only a transient colonization, since fecal propionibacteria population in human volunteer's decreases after ceasing the ingestion of propionibacteria [198,199]. *P. freudenreichii* produces several beneficial metabolites, allows specific changes, as microbiota and intestinal immunity modulations [192]. Some strains of dairy propionibacteria are already used in probiotic preparations, alone or in combination with lactic acid bacteria and/or bifidobacteria [192]. Recently, the spray-drying was shown as a better alternative method to dry probiotic bacteria, since energy costs are lower and the process is sustainable [200,201]. *P. freudenreichii* was shown to tolerate stresses undergone during different technological stresses, which will lead to the development of several fermented ingredients to exert probiotic potential of dairy propionibacteria for improving animal and human health.

4.3.1. Molecular mechanisms of *P. freudenreichii* beneficial effects

Regarding *P. freudenreichii*, animal studies and clinical trials indicate its ability to modulate gut immunity and microbiota, specifically in the context of UC. *P. freudenreichii* was shown to prevent trinitrobenzene sulfonic acid (TNBS) induced colitis in conventional mice, alone or associated with other probiotic bacteria [202,203]. Immunomodulation by *P. freudenreichii* was further evidenced in pigs, by decreasing plasma haptoglobin and proinflammatory cytokines (IL-8 and TNF- α) in gut mucosa, after lipopolysaccharides (LPS) stimulation *ex vivo* [198]. Recently, a probiotic mixture containing both *Lactobacillus rhamnosus* and *P. freudenreichii* was tested in humanized mice (colonized with human microbiota) consuming

a high-fat diet [204]. It tended to down-regulate both intestinal and systemic pro-inflammatory changes induced by the diet. A commercial preparation of bifidogenic growth stimulator (BGS), which is produced by *P. freudenreichii* ET-3, led to an improvement in the clinical activity scores of UC patients [205,206]. In the same study, patients also showed a decrease in the endoscopic index and an improvement in serum hemoglobin and albumin concentrations. Although, no clinical evidences on propionibacteria consumption within CRC patients exist, when tested in healthy men, this probiotic mixture reduced fecal α -glucosidase, which is associated with carcinogenesis [207,208]. Studies strongly suggest that those anti-inflammatory and potential anti-cancerous effects are related with the molecular factors of *P. freudenreichii* such as metabolites, S-layer proteins, short fatty acids, and 1, 4-dihydroxy-2-naphtoic acid [209–211].

4.3.1.1. S-layers proteins

S-layer proteins (Slps) constitute a surface-exposed proteinaceous lattice, non-covalently anchored to the cell wall via Surface Layer Homology (SLH) domains. This structure is present in many Gram-positive bacteria other than propionibacteria [212,213]. *P. freudenreichii* strains have seven genes encoding Slps proteins, exhibiting a wide variety of sequences between species but also within the same species [195]. S-layer proteins play various functions: adhesion, virulence factors, transport of molecules, masking of receptors to phages, and protection against environmental stresses [212,213]. The stimulation of Peripheral Blood Mononuclear Cells (PBMC) with *P. freudenreichii* Slps proteins mixture leads to the release of regulatory IL-10, in a dose-dependent manner. When applied in conjunction with a proinflammatory stimulus such as *Lactococcus lactis* MG1363 or *Escherichia coli* EPS, *P. freudenreichii* Slps considerably reduce the induction of the proinflammatory cytokines IL-12, IFN- γ and TNF- α [214]. The presence of a capsule of exopolysaccharides in several strains of *P. freudenreichii* blocks the immunostimulation of PBMCs, but the deletion of this EPS capsule by genetic mutation restores the immunomodulatory properties in the mutant [215,216]. This indicates a key role of surface proteins as PAMPs in this probiotic/host cross-talk. A further molecular study specified that the immunomodulatory properties do not result from the presence of one single Slp protein but rather from a combination of several surface layer protein species [217].

4.3.1.2. Short-chain fatty acids

P. freudenreichii, among other dairy propionibacteria species, produces mainly acetate and propionate as SCFAs in ratio 2:1 by anaerobic fermentation of carbohydrates or organic acids [190]. Propionate and acetate were identified as responsible for the anti-cancerous effect of dairy propionibacteria in colorectal and gastric cancerous cells. The pro-apoptotic effect, confirmed in an animal model of carcinogenesis, was studied and the molecular mechanism

was determined [218–221]. SCFAs activate firstly the apoptotic intrinsic pathway, by acting on the mitochondria adenine nucleotide translocator (ANT) pore. The ANT activation leads to mitochondria depolarization and permeabilisation; and then leakage of cytochrome C and caspase activation. Furthermore, as demonstrated by Cousin *et al.* (2016), SCFAs could act on the extrinsic apoptotic pathway by enhancing the cytotoxicity of the TNF-Related Apoptosis-Inducing Ligand (TRAIL) cytokine treatment in HT-29 cells [222] and by inducing expression of the corresponding R2/DR5 receptor, a TNF receptor super family member that mediates apoptosis by activating the extrinsic apoptotic death pathway. A combination lead to a modulation of genes expression involved in apoptosis, decreasing FLIPL and XIAP expression, which are two apoptosis inhibitors, regulating extrinsic and intrinsic cell death pathways respectively. SCFAs was demonstrated to have a Histone Deacetylase (HDACs) inhibitory activity in HT29 cells, which cause cell cycle arrest and p21 expression [222]. HDACs inhibition seems to be induced in part by SCFAs activated G-protein-coupled receptors, which are known to modulate gut immune system [223]. Finally, SCFAs treatments increased of NOD-like receptors and cytokine-cytokine receptors interaction gene expression, known to play a role in immune response [222]. Finally, *P. freudenreichii* consumption by humans increase SCFAs in feces, suggesting the possibility to modulate gut SCFAs concentrations for preventing CRC occurrence.

4.3.1.3. DHNA

Dairy probionibacteria, including *P. freudenreichii*, produce a vitamin K₂ (or menaquinone) biosynthesis intermediate, called 1,4-dihydroxy-2-naphtoic acid (DHNA) [224-226]. It is considered as bifidogenic component and modulates animal and human microbiota, in healthy and disease context. DHNA was shown to be able to stimulate *in vitro* and *in vivo* bifidobacteria growth. Indeed, the consumption of dried cultures of the *P. freudenreichii* ET-3 strain leads to an increased population of bifidobacteria within the human gut microbiota in healthy human volunteers [227,228]. Similar results were observed using a cell-free culture supernatant of *P. freudenreichii*, which was called bifidogenic growth stimulator (BGS) [229]. In addition, DHNA treatment was shown to restore Lactobacillus and Enterobacteriaceae flora in dextran sulfate sodium (DSS)-induced-colitis in mice [230]. It induces also the expression of anti-microbial C-type lectin Reg III protein family, which certainly affects the microbiota [231]. DHNA is an anti-inflammatory metabolite which prevents inflammation in different murine colitis models [230–232]. It decreased the lymphocytes infiltration in tissues by reducing cell adhesion molecules expression (MAdCAM-1 or VCAM-1), in a mice colitis model [230,232]. Those adhesion molecules are highly expressed In IBD patients, which exacerbate the inflammation by increasing immune cells infiltration in tissues. DHNA acts via the aryl hydrocarbon receptor (AhR) activation, a transcriptional factor involved in inflammation [231]. AhR activation was shown to be involved in the inhibition of secretion of proinflammatory

cytokines. Indeed, the inhibition of proinflammatory cytokine IL6 in LPS-stimulated macrophages was related to AhR activation by DHNA [231].

5. Discussion

The Scientific community along with some enterprises have been through a technological race to sequence and characterize the genome of GIT commensal bacteria, the so-called gut microbiota. This approach is crucial to understand the interactions and associations within this high complexity biological system and with the host. The human intestinal microbiota composition is not only considered in the healthy state, but also in the context of disease, in order to understand the dysregulation of the cross talk mechanisms that are involved. Such dysregulation, especially when immune system is affected, lead to IBD, cancer or other inflammatory disorders, such as mucositis [7,18,19,46,64]. It is clear that the use of probiotics with anti-inflammatory or immunomodulatory properties, may change the microbiota composition, enhance epithelial barrier function and dampen immune responses by modulating inflammatory signaling pathways. Based on this rationale, several research groups aimed at treating gastrointestinal inflammatory disorders [103,127]. Due to adverse conditions of the GIT environment, it is important that probiotics be screened, in order to select tolerant strains to avoid massive bacterial death and loss of probiotic efficacy, while favoring robustness against digestive stresses, adherence to intestinal epithelium and long persistence in the host.

In this context, protection of probiotics could optimize fitness of sensitive strains or even improve tolerant strains, and consequently increase their beneficial effects in the GIT. Technological processes like microencapsulation, using biocompatible materials, or a combination of several processes that are used to make functional foods, have indeed been shown to enhance probiotic bacteria activity [182,233-235]. Currently, wide varieties of probiotics are available within commercial dairy products including fresh milk, yogurt and cheese. Interestingly, these commercial products may improve probiotics by converting biomolecules into dairy metabolites which can help in probiotic effect such as conjugated fatty acid, β -galactosidase enzyme, etc. [161,236,237]. For instance, fermented milk with *L. casei* BL23 showed a significant reduction of the clinical state of colitis in mice, suggesting that it is safe and efficient to use dairy fermented foods with probiotic strains in animal models [178]. In addition, this might be the initial step for their clinical use. Therefore, the search for new studies in different models of diseases should be encouraged [178,179].

Recent studies have pointed out the emergence of the potential probiotic application for *P.freudenreichii*, and other dairy propionibacteria, used extensively for Emmental cheese ripening, in the treatment of different gastrointestinal inflammatory diseases such as mucositis, colitis and in CRC using a rat model. In addition, ongoing studies investigate the benefit of designer fermented dairy products in the context of clinical trials (NCT02488954)

[104,105,187,188,238–240]. Finally, exploration of probiotic aptitudes in robust, traditional and easy-to-implement fermentation starter bacteria is a promising area of research.

6. Conclusion

The potential of different probiotic bacteria strains in treating GIT disorders, in animal models and in clinical trials, strongly suggests that they open avenues for the development of novel clinical biotherapies. We believe that the use of functional dairy foods is a useful way for enhancing immunological effects, as they provide additional beneficial properties and serve as excellent protection matrices for probiotic bacteria. In this context, exploring the potential of the variety of lactic acid and propionic acid bacteria selected by centuries of traditional fermentation worldwide, will allow identification of yet unknown superbugs.

7. Reference

1. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. *Genes Nutr.* 2011; 6(3): 209-40.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol.* 2003; 3(7): 521–33.
3. Sartor RB. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol.* 2006; 3(7): 390–407.
4. Sartor RB. Microbial and Dietary Factors in the Pathogenesis of Chronic, Immune-Mediated Intestinal Inflammation. In: Blumberg RS, Neurath MF, editors. *Immune Mechanisms in Inflammatory Bowel Disease* [Internet]. Springer New York; 2006 [cited 2017 May 6]. p. 35–54. (Advances in Experimental Medicine and Biology). Available from: http://link.springer.com/chapter/10.1007/0-387-33778-4_4
5. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. *World J Gastroenterol WJG.* 2015; 21(29): 8787–803.
6. Kalliomäki MA, Walker WA. Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium. *Gastroenterol Clin North Am.* 2005; 34(3): 383–399, vii.
7. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. *Nat Rev Immunol.* 2008; 8(6): 411–20.
8. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. *Annu Rev Immunol.* 2010; 28: 623–67.
9. Santos Rocha C, Lakhdari O, Blottière HM, Blugeon S, Sokol H, Bermúdez-Humarán LG, et al. Anti-inflammatory properties of dairy lactobacilli. *Inflamm Bowel Dis.* 2012; 18(4): 657–66.
10. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis* [Internet]. 2015 [cited 2017 May 6]; 26. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315779/>
11. Buttó LF, Haller D. Dysbiosis in intestinal inflammation: Cause or consequence. *Int J Med Microbiol IJMM.* 2016; 306(5): 302–9.
12. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic Analysis of the Human Distal Gut Microbiome. *Science.* 2006; 312 (5778): 1355–9.

13. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology*. 2008; 134(2): 577–94.
14. Kumar A, Daga R, Vijayaragavan P, Prakash A, Singh RK, Behari A, et al. Anterior resection for rectal carcinoma - risk factors for anastomotic leaks and strictures. *World J Gastroenterol WJG*. 2011; 17(11): 1475–9.
15. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. *Curr Issues Intest Microbiol*. 2001; 2(2): 43–53.
16. Neish AS. Microbes in gastrointestinal health and disease. *Gastroenterology*. 2009; 136(1): 65–80.
17. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. *Best Pract Res Clin Gastroenterol*. 2003; 17(5): 725–40.
18. Thompson CC, Amaral GR, Campeão M, Edwards RA, Polz MF, Dutilh BE, et al. Microbial taxonomy in the post-genomic era: rebuilding from scratch? *Arch Microbiol*. 2015; 197(3): 359–70.
19. Uyeno Y, Shigemori S, Shimosato T. Effect of Probiotics/Prebiotics on Cattle Health and Productivity. *Microbes Environ*. 2015; 30(2): 126–32.
20. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell*. 2006; 124(4): 837–48.
21. Velasquez-Manoff M. Gut microbiome: the peacekeepers. *Nature*. 2015; 518 (7540): S3-11.
22. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. *Science*. 2005; 308 (5728): 1635–8.
23. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010; 464 (7285): 59–65.
24. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol*. 2010;10 (3): 159–69.
25. de Vos WM, de Vos EAJ. Role of the intestinal microbiome in health and disease: from correlation to causation. *Nutr Rev*. 2012; 70 Suppl 1: S45-56.
26. Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, McGuirk P, van Eden W, et al. Mechanisms of disease: the hygiene hypothesis revisited. *Nat Clin Pract Gastroenterol Hepatol*. 2006; 3(5): 275–84.
27. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. *Nat Rev Gastroenterol Hepatol*. 2012; 9 (10): 577–89.
28. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. *Front Microbiol* [Internet]. 2014 [cited 2017 May 6]; 5. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010744/>
29. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. *J Gastroenterol*. 2014 ; 49 (5): 785–98.
30. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. *Cell Host Microbe*. 2015; 17 (5): 553–64.
31. Rajilić-Stojanović M, Smidt H, de Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. *Environ Microbiol*. 2007; 9 (9): 2125–36.
32. Neu J, Rushing J. Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis. *Clin Perinatol*. 2011; 38 (2): 321–31.

33. Rehman A, Rausch P, Wang J, Skieceviciene J, Kiudelis G, Bhagalia K, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. *Gut*. 2016; 65(2): 238–48.
34. Bernstein CN. Treatment of IBD: where we are and where we are going. *Am J Gastroenterol*. 2015; 110 (1): 14–26.
35. Chang C, Lin H. Dysbiosis in gastrointestinal disorders. *Best Pract Res Clin Gastroenterol*. 2016; 30 (1): 3–15.
36. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014; 505 (7484): 559–63.
37. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium prausnitzii*. *Br J Nutr*. 2009; 101 (4): 541–50.
38. Martínez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. *PLoS One*. 2010; 5 (11): e15046.
39. Wang M, Ahrné S, Jeppsson B, Molin G. Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. *FEMS Microbiol Ecol*. 2005; 54 (2): 219–31.
40. Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. *Mol Microbiol*. 2006; 59 (6): 1639–50.
41. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep*. 2006; 7 (7): 688–93.
42. Lennon G, Balfé Á, Bambury N, Lavelle A, Maguire A, Docherty NG, et al. Correlations between colonic crypt mucin chemotype, inflammatory grade and *Desulfovibrio* species in ulcerative colitis. *Colorectal Dis Off J Assoc Coloproctology G B Irel*. 2014; 16 (5): O161-169.
43. Walter J. Ecological Role of Lactobacilli in the Gastrointestinal Tract: Implications for Fundamental and Biomedical Research. *Appl Environ Microbiol*. 2008; 74 (16): 4985–96.
44. Prakash S, Tomaro-Duchesneau C, Saha S, Cantor A. The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial Cells. *BioMed Res Int*. 2011; 2011: e981214.
45. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. *Biol Targets Ther*. 2011; 5: 71–86.
46. Wells JM, Loonen LMP, Karczewski JM. The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. *Int J Med Microbiol IJMM*. 2010; 300 (1): 41–8.
47. Royet J, Gupta D, Dziarski R. Peptidoglycan recognition proteins: modulators of the microbiome and inflammation. *Nat Rev Immunol*. 2011; 11 (12): 837–51.
48. Sommer F, Bäckhed F. The gut microbiota--masters of host development and physiology. *Nat Rev Microbiol*. 2013; 11 (4): 227–38.
49. Kashyap DR, Rompca A, Gaballa A, Helmann JD, Chan J, Chang CJ, et al. Peptidoglycan recognition proteins kill bacteria by inducing oxidative, thiol, and metal stress. *PLoS Pathog*. 2014; 10 (7): e1004280.
50. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol*. 2014; 14 (3): 141–53.
51. Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol*. 2004; 4(7): 499–511.
52. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl J-P. Molecular and cellular basis of microflora-host interactions. *J Nutr*. 2007; 137 (3 Suppl 2): 756S–72S.
53. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Host interactions of probiotic bacterial surface molecules: com-

parison with commensals and pathogens. *Nat Rev Microbiol*. 2010; 8 (3): 171–84.

54. Carlsson AH, Yakymenko O, Olivier I, Håkansson F, Postma E, Keita AV, et al. Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. *Scand J Gastroenterol*. 2013; 48 (10): 1136–44.

55. Johansson MEV, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. *Nat Rev Gastroenterol Hepatol*. 2013; 10 (6): 352–61.

56. Uematsu S, Fujimoto K, Jang MH, Yang B-G, Jung Y-J, Nishiyama M, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. *Nat Immunol*. 2008; 9 (7): 769–76.

57. Kinnebrew MA, Buffie CG, Diehl GE, Zenewicz LA, Leiner I, Hohl TM, et al. Intestinal CD103+ CD11b+ lamina propria dendritic cells instruct intestinal epithelial cells to express antimicrobial proteins in response to Toll-like receptor 5 activation. *Immunity*. 2012; 36 (2): 276–87.

58. de Kivit S, Tobin MC, Forsyth CB, Keshavarzian A, Landay AL. Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics. *Front Immunol* [Internet]. 2014 [cited 2017 May 6]; 5. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927311/>

59. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. *Immunol Today*. 1999; 20(6): 267–77.

60. Suzuki K, Fagarasan S. How host-bacterial interactions lead to IgA synthesis in the gut. *Trends Immunol*. 2008; 29 (11): 523–31.

61. Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. *Nat Immunol*. 2013; 14 (7): 660–7.

62. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll” ? *World J Gastroenterol*. 2006; 12 (12): 1829–41.

63. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. *Annu Rev Immunol*. 2009; 27: 313–38.

64. O’Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. *Nat Rev Immunol*. 2013; 13 (6): 453–60.

65. Stepaniuk P, Bernstein CN, Targownik LE, Singh H. Characterization of inflammatory bowel disease in elderly patients: A review of epidemiology, current practices and outcomes of current management strategies. *Can J Gastroenterol Hepatol*. 2015; 29 (6): 327–33.

66. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl*. 1989; 170: 2-6; discussion 16-19.

67. Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. *Inflamm Bowel Dis*. 2015; 21 (4): 824–31.

68. Cho JH. Inflammatory bowel disease: Genetic and epidemiologic considerations. *World J Gastroenterol WJG*. 2008; 14 (3): 338–47.

69. Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. *World J Gastroenterol WJG*. 2015; 21(1): 21–46.

70. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Gut*. 1996; 39 (5): 690–7.

71. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012; 142 (1): 46–54. e42; quiz e30.
72. Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol*. 2015;12(4): 205–17.
73. Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. *Nat Rev Microbiol*. 2010; 8 (8): 564–77.
74. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. *PLoS Comput Biol*. 2013; 9 (1): e1002863.
75. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). *Clin Exp Immunol*. 1995; 102 (3): 448–55.
76. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc*. 2004 Apr;2(4):309–13.
77. Gasche C, Chang CL, Rhees J, Goel A, Boland CR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. *Cancer Res*. 2001; 61 (20): 7444–8.
78. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. *Gastroenterology*. 2011; 140 (6): 1807–16.
79. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem*. 1997; 272 (33): 20313–6.
80. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? *Aliment Pharmacol Ther*. 2002; 16 (12): 1997–2015.
81. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res*. 1991; 51 (3): 794–8.
82. O’Keefe SJD, Chung D, Mahmoud N, Sepulveda AR, Manafe M, Arch J, et al. Why do African Americans get more colon cancer than Native Africans? *J Nutr*. 2007; 137 (1 Suppl): 175S–182S.
83. Conlon MA, Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. *Nutrients*. 2014; 7 (1): 17–44.
84. Soares PMG, Mota JM, Souza EP, Justino PFC, Franco AX, Cunha FQ, et al. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. *Cytokine*. 2013; 61 (1): 46–9.
85. Pedroso SHSP, Vieira AT, Bastos RW, Oliveira JS, Cartelle CT, Arantes RME, et al. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. *Microbiol Read Engl*. 2015;161 (10): 1950–60.
86. McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. *Oral Oncol*. 1998; 34 (6): 484–90.
87. Sonis ST. The pathobiology of mucositis. *Nat Rev Cancer*. 2004; 4 (4): 277–84.
88. Chang C-T, Ho T-Y, Lin H, Liang J-A, Huang H-C, Li C-C, et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor- κ B activation by transcriptomic analysis and in vivo bioluminescence imaging. *PloS One*. 2012; 7 (3): e31808.
89. Antunes MM, Leocádio PCL, Teixeira LG, Leonel AJ, Cara DC, Menezes GB, et al. Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model. *JPEN*

J Parenter Enteral Nutr. 2016; 40 (2): 279–86.

90. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh ASJ, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. *Int J Exp Pathol*. 2009; 90 (5): 489–99.

91. von Bültzingslöwen I, Brennan MT, Spijkervet FKL, Logan R, Stringer A, Raber-Durlacher JE, et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. *Support Care Cancer Off J Multinatl Assoc Support Care Cancer*. 2006; 14 (6): 519–27.

92. van Vliet MJ, Harmsen HJM, de Bont ESJM, Tissing WJE. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. *PLoS Pathog*. 2010; 6 (5): e1000879.

93. Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues Â, Dias PC, et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. *BMC Cancer* [Internet]. 2010 [cited 2017 May 6]; 10(1). Available from: <http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-470>

94. Stringer AM, Logan RM. The role of oral flora in the development of chemotherapy-induced oral mucositis. *J Oral Pathol Med*. 2015; 44 (2): 81–7.

95. Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM, et al. Intestinal microflora and digestive toxicity of irinotecan in mice. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2006; 12 (4): 1299–307.

96. Ljungh A, Wadström T. Lactic acid bacteria as probiotics. *Curr Issues Intest Microbiol*. 2006; 7 (2): 73–89.

97. Santos Rocha C, Gomes-Santos AC, Garcias Moreira T, de Azevedo M, Diniz Luerce T, Mariadassou M, et al. Local and systemic immune mechanisms underlying the anti-colitis effects of the dairy bacterium *Lactobacillus delbrueckii*. *PLoS One*. 2014; 9 (1): e85923.

98. Quinto EJ, Jiménez P, Caro I, Tejero J, Mateo J, Girbés T. Probiotic Lactic Acid Bacteria: A Review. *Food Nutr Sci*. 2014; 05 (18): 1765–75.

99. Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, et al. Anti-inflammatory effects of *Lactococcus lactis* NCDO 2118 during the remission period of chemically induced colitis. *Gut Pathog*. 2014; 6: 33.

100. Thomas H. IBD: Probiotics for IBD: a need for histamine? *Nat Rev Gastroenterol Hepatol*. 2016; 13 (2): 62–3.

101. Carvalho RD, Breyner N, Menezes-Garcia Z, Rodrigues NM, Lemos L, Maioli TU, et al. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy *Lactococcus lactis* NZ9000 in the prevention of intestinal mucositis. *Microb Cell Factories*. 2017; 16 (1): 27.

102. Food and Agriculture Organization of the United Nations, World Health Organization, editors. Probiotics in food: health and nutritional properties and guidelines for evaluation. Rome: Food and Agriculture Organization of the United Nations : World Health Organization; 2006. 50 p. (FAO food and nutrition paper).

103. Food and Agriculture Organization of the United Nations, World Health Organization, editors. Probiotics in food: health and nutritional properties and guidelines for evaluation. Rome: Food and Agriculture Organization of the United Nations : World Health Organization; 2002. 50 p. (FAO food and nutrition paper).

104. Plé C, Richoux R, Jardin J, Nurdin M, Briard-Bion V, Parayre S, et al. Single-strain starter experimental cheese reveals anti-inflammatory effect of *Propionibacterium freudenreichii* CIRM BIA 129 in TNBS-colitis model. *J Funct Foods*. 2015; 18, Part A: 575–85.

105. Plé C, Breton J, Richoux R, Nurdin M, Deutsch S-M, Falentin H, et al. Combining selected immunomodulatory *Propionibacterium freudenreichii* and *Lactobacillus delbrueckii* strains: Reverse engineering development of an anti-inflammatory cheese. *Mol Nutr Food Res*. 2016; 60 (4): 935–48.

106. Ouwehand AC, Suomalainen T, Tölkö S, Salminen S. In vitro adhesion of propionic acid bacteria to human intestinal mucus. *Le Lait*. 2002; 82 (1): 123–30.
107. Carvalho RDDO, Carmo FLR do, Junior A de O, Langella P, Chatel J-M, Bermudez-Humaran LG, et al. Use of wild type or recombinant Lactic Acid Bacteria as an alternative treatment for gastrointestinal inflammatory diseases: A focus on Inflammatory Bowel Diseases and Mucositis. *Front Microbiol* [Internet]. 2017 [cited 2017 May 6]; 8. Available from: <http://journal.frontiersin.org/article/10.3389/fmicb.2017.00800/abstract>
108. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA. In vitro and in vivo effects of the probiotic *Escherichia coli* strain M-17: immunomodulation and attenuation of murine colitis. *Br J Nutr*. 2008; 100 (3): 530–41.
109. Chung YW, Choi JH, Oh T-Y, Eun CS, Han DS. *Lactobacillus casei* prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice: *L. casei* prevents experimental colitis. *Clin Exp Immunol*. 2007; 151 (1): 182–9.
110. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008; 105 (43): 16731–6.
111. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. *J Gastroenterol Hepatol*. 2008; 23 (12): 1834–9.
112. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. *J Immunol Baltim Md 1950*. 2005; 174 (6): 3237–46.
113. Macho Fernandez E, Fernandez EM, Valenti V, Rockel C, Hermann C, Pot B, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. *Gut*. 2011; 60 (8): 1050–9.
114. Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G. Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis. *Dig Dis Sci*. 2008; 53 (9): 2464–73.
115. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature*. 2008; 453 (7195): 620–5.
116. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. *Gut*. 2003; 52 (7): 975–80.
117. Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, et al. Probiotic *Lactobacillus*-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. *Clin Exp Immunol*. 2005; 140 (3): 417–26.
118. Sivieri K, Spinardi-Barbisan ALT, Barbisan LF, Bedani R, Pauly ND, Carlos IZ, et al. Probiotic *Enterococcus faecium* CRL 183 inhibit chemically induced colon cancer in male Wistar rats. *Eur Food Res Technol*. 2008 Dec;228(2):231–7.
119. Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon H-W, et al. *Saccharomyces boulardii* inhibits EGF receptor signaling and intestinal tumor growth in *Apc(min)* mice. *Gastroenterology*. 2009; 137(3): 914–23.
120. Walia S, Kamal R, Kanwar SS, Dhawan DK. Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats. *Nutr Cancer*. 2015; 67 (4): 603–11.
121. Zhang M, Fan X, Fang B, Zhu C, Zhu J, Ren F. Effects of *Lactobacillus salivarius* Ren on cancer prevention and intestinal microbiota in 1, 2-dimethylhydrazine-induced rat model. *J Microbiol Seoul Korea*. 2015; 53 (6): 398–405.

122. Lee HA, Kim H, Lee K-W, Park K-Y. Dead Nano-Sized *Lactobacillus plantarum* Inhibits Azoxymethane/Dextran Sulfate Sodium-Induced Colon Cancer in Balb/c Mice. *J Med Food*. 2015; 18 (12): 1400–5.
123. Verma A, Shukla G. Probiotics *Lactobacillus rhamnosus* GG, *Lactobacillus acidophilus* suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. *Nutr Cancer*. 2013; 65 (1): 84–91.
124. Lenoir M, Del Carmen S, Cortes-Perez NG, Lozano-Ojalvo D, Muñoz-Provencio D, Chain F, et al. *Lactobacillus casei* BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. *J Gastroenterol*. 2016; 51 (9): 862–73.
125. Dubey V, Ghosh AR, Bishayee K, Khuda-Bukhsh AR. Appraisal of the anti-cancer potential of probiotic *Pediococcus pentosaceus* GS4 against colon cancer: in vitro and in vivo approaches. *J Funct Foods*. 2016; 23: 66–79.
126. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. *Am J Physiol Gastrointest Liver Physiol*. 2010; 298 (6): G807-819.
127. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Genes and molecules of lactobacilli supporting probiotic action. *Microbiol Mol Biol Rev MMBR*. 2008; 72(4): 728–764, Table of Contents.
128. Ogawa J, Matsumura K, Kishino S, Omura Y, Shimizu S. Conjugated Linoleic Acid Accumulation via 10-Hydroxy-12-Octadecaenoic Acid during Microaerobic Transformation of Linoleic Acid by *Lactobacillus acidophilus*. *Appl Environ Microbiol*. 2001; 67 (3): 1246–52.
129. Liévin-Le Moal V, Sarrazin-Davila LE, Servin AL. An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of *Lactobacillus acidophilus* strain LB against nonrotavirus diarrhea. *Pediatrics*. 2007; 120(4): e795-803.
130. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, et al. Secreted bioactive factors from *Bifidobacterium infantis* enhance epithelial cell barrier function. *Am J Physiol Gastrointest Liver Physiol*. 2008; 295 (5): G1025-1034.
131. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, et al. *Lactobacillus plantarum* MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. *BMC Microbiol*. 2010; 10: 316.
132. Eun CS, Kim YS, Han DS, Choi JH, Lee AR, Park YK. *Lactobacillus casei* prevents impaired barrier function in intestinal epithelial cells. *APMIS Acta Pathol Microbiol Immunol Scand*. 2011; 119 (1): 49–56.
133. Zhang L, Li N, Caicedo R, Neu J. Alive and dead *Lactobacillus rhamnosus* GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. *J Nutr*. 2005 Jul;135 (7): 1752–6.
134. Jijon HB, Panenka WJ, Madsen KL, Parsons HG. MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. *Am J Physiol Cell Physiol*. 2002; 283 (1): C31-41.
135. Ma D, Forsythe P, Bienenstock J. Live *Lactobacillus rhamnosus* [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. *Infect Immun*. 2004; 72 (9): 5308–14.
136. Nishitani Y, Tanoue T, Yamada K, Ishida T, Yoshida M, Azuma T, et al. *Lactococcus lactis* subsp. *cremoris* FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. *Int Immunopharmacol*. 2009; 9 (12): 1444–51.
137. Thierry A, Deutsch S-M, Falentin H, Dalmaso M, Cousin FJ, Jan G. New insights into physiology and metabolism of *Propionibacterium freudenreichii*. *Int J Food Microbiol*. 2011; 149 (1): 19–27.
138. Le Maréchal C, Peton V, Plé C, Vroland C, Jardin J, Briard-Bion V, et al. Surface proteins of *Propionibacterium freudenreichii* are involved in its anti-inflammatory properties. *J Proteomics*. 2015; 113: 447–61.

139. Cotter PD, Hill C. Surviving the Acid Test: Responses of Gram-Positive Bacteria to Low pH. *Microbiol Mol Biol Rev.* 2003 Sep; 67(3): 429–53.
140. Yamamoto N, Masujima Y, Takano T. Reduction of membrane-bound ATPase activity in a *Lactobacillus helveticus* strain with slower growth at low pH. *FEMS Microbiol Lett.* 1996;138 (2): 179–84.
141. Yokota A, Amachi S, Ishii S, Tomita F. Acid sensitivity of a mutant of *Lactococcus lactis* subsp. *lactis* C2 with reduced membrane-bound ATPase activity. *Biosci Biotechnol Biochem.* 1995; 59 (10): 2004–7.
142. Sanders JW, Leenhouts K, Burghoorn J, Brands JR, Venema G, Kok J. A chloride-inducible acid resistance mechanism in *Lactococcus lactis* and its regulation. *Mol Microbiol.* 1998; 27 (2): 299–310.
143. Ueno Y, Hayakawa K, Takahashi S, Oda K. Purification and characterization of glutamate decarboxylase from *Lactobacillus brevis* IFO 12005. *Biosci Biotechnol Biochem.* 1997; 61 (7): 1168–71.
144. Champomier-Vergès MC, Chaillou S, Cornet M, Zagorec M. *Lactobacillus sakei*: recent developments and future prospects. *Res Microbiol.* 2001; 152 (10): 839–48.
145. Olsen EB, Russell JB, Henick-Kling T. Electrogenic L-malate transport by *Lactobacillus plantarum*: a basis for energy derivation from malolactic fermentation. *J Bacteriol.* 1991; 173(19): 6199–206.
146. Renault P, Gaillardin C, Heslot H. Role of malolactic fermentation in lactic acid bacteria. *Biochimie.* 1988; 70(3): 375–9.
147. García-Quintáns N, Magni C, de Mendoza D, López P. The citrate transport system of *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* is induced by acid stress. *Appl Environ Microbiol.* 1998; 64 (3): 850–7.
148. Cotter PD, Hill C. Surviving the Acid Test: Responses of Gram-Positive Bacteria to Low pH. *Microbiol Mol Biol Rev.* 2003; 67 (3): 429–53.
149. Lim EM, Ehrlich SD, Maguin E. Identification of stress-inducible proteins in *Lactobacillus delbrueckii* subsp. *bulgaricus*. *Electrophoresis.* 2000; 21(12): 2557–61.
150. Ruiz L, Margolles A, Sánchez B. Bile resistance mechanisms in *Lactobacillus* and *Bifidobacterium*. *Front Microbiol* [Internet]. 2013 Dec 24 [cited 2017 Apr 10];4. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872040/>
151. Begley M, Hill C, Gahan CGM. Bile Salt Hydrolase Activity in Probiotics. *Appl Environ Microbiol.* 2006; 72 (3): 1729–38.
152. Cremers CM, Knoefler D, Vitvitsky V, Banerjee R, Jakob U. Bile salts act as effective protein-unfolding agents and instigators of disulfide stress in vivo. *Proc Natl Acad Sci U S A.* 2014; 111 (16): E1610–9.
153. Bernstein H, Payne CM, Bernstein C, Schneider J, Beard SE, Crowley CL. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. *Toxicol Lett.* 1999; 108 (1): 37–46.
154. Cabral DJ, Small DM, Lilly HS, Hamilton JA. Transbilayer movement of bile acids in model membranes. *Biochemistry (Mosc).* 1987; 26 (7): 1801–4.
155. Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. *Proc Natl Acad Sci U S A.* 2008;105 (36): 13580–5.
156. Piddock LJV. Multidrug-resistance efflux pumps - not just for resistance. *Nat Rev Microbiol.* 2006; 4(8): 629–36.
157. Pfeiler EA, Azcarate-Peril MA, Klaenhammer TR. Characterization of a novel bile-inducible operon encoding a two-component regulatory system in *Lactobacillus acidophilus*. *J Bacteriol.* 2007; 189 (13): 4624–34.

158. Maleki F, Khosravi A, Nasser A, Taghinejad H, Azizian M. Bacterial Heat Shock Protein Activity. *J Clin Diagn Res JCDR*. 2016; 10 (3): BE01-BE03.
159. Papadimitriou K, Alegría Á, Bron PA, Angelis M de, Gobbetti M, Kleerebezem M, et al. Stress Physiology of Lactic Acid Bacteria. *Microbiol Mol Biol Rev*. 2016; 80(3): 837–90.
160. Yura T, Nagai H, Mori H. Regulation of the heat-shock response in bacteria. *Annu Rev Microbiol*. 1993; 47: 321–50.
161. Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Foligné B, et al. Health benefits of fermented foods: microbiota and beyond. *Curr Opin Biotechnol*. 2017; 44: 94–102.
162. Champagne CP, Fustier P. Microencapsulation for the improved delivery of bioactive compounds into foods. *Curr Opin Biotechnol*. 2007; 18(2): 184–90.
163. Zuidam NJ, Shimoni E. Overview of Microencapsulates for Use in Food Products or Processes and Methods to Make Them. In: Zuidam NJ, Nedovic V, editors. *Encapsulation Technologies for Active Food Ingredients and Food Processing* [Internet]. Springer New York; 2010 [cited 2017 May 4]. p. 3–29. Available from: http://link.springer.com/chapter/10.1007/978-1-4419-1008-0_2
164. Rosa do Carmo FL, Dias Carvalho R. Therapeutic DNA Vaccines: The Final Step for Success. *J Bacteriol Parasitol* [Internet]. 2017 [cited 2017 May 4];08(01). Available from: <https://www.omicsonline.org/open-access/therapeutic-dna-vaccines-the-final-step-for-success-2155-9597-1000e125.php?aid=87046>
165. Chavarri M, Maranon I, Carmen M. Encapsulation Technology to Protect Probiotic Bacteria. In: Rigobelo E, editor. *Probiotics* [Internet]. InTech; 2012 [cited 2017 May 4]. Available from: <http://www.intechopen.com/books/probiotics/encapsulation-technology-to-protect-probiotic-bacteria>
166. Yeung TW, Üçok EF, Tiani KA, McClements DJ, Sela DA. Microencapsulation in Alginate and Chitosan Microgels to Enhance Viability of *Bifidobacterium longum* for Oral Delivery. *Front Microbiol* [Internet]. 2016 Apr 19 [cited 2017 May 4]; 7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835488/>
167. Mandal S, Hati S, Puniya AK, Khamrui K, Singh K. Enhancement of survival of alginate-encapsulated *Lactobacillus casei* NCDC 298. *J Sci Food Agric*. 2014 Aug; 94(10):1994–2001.
168. Yeung TW, Arroyo-Maya IJ, McClements DJ, Sela DA. Microencapsulation of probiotics in hydrogel particles: enhancing *Lactococcus lactis* subsp. *cremoris* LM0230 viability using calcium alginate beads. *Food Funct*. 2016; 7(4):1797–804.
169. Livney YD. Milk proteins as vehicles for bioactives. *Curr Opin Colloid Interface Sci*. 2010; 15 (1–2): 73–83.
170. Wang X, Zhao X, Huang D, Pan X, Qi Y, Yang Y, et al. Proteomic analysis and cross species comparison of casein fractions from the milk of dairy animals. *Sci Rep* [Internet]. 2017 Feb 27 [cited 2017 May 4]; 7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327394/>
171. Guo M, Wang G. Milk Protein Polymer and Its Application in Environmentally Safe Adhesives. *Polymers*. 2016; 8 (9): 324.
172. Guerin J, Petit J, Burgain J, Borges F, Bhandari B, Perroud C, et al. *Lactobacillus rhamnosus* GG encapsulation by spray-drying: Milk proteins clotting control to produce innovative matrices. *J Food Eng*. 2017;193: 10–9.
173. Heidebach T, Först P, Kulozik U. Microencapsulation of probiotic cells by means of rennet-gelation of milk proteins. *Food Hydrocoll*. 2009; 23 (7): 1670–7.
174. Heidebach T, Först P, Kulozik U. Transglutaminase-induced caseinate gelation for the microencapsulation of probiotic cells. *Int Dairy J*. 2009; 19(2): 77–84.

175. Silva JPS e, Freitas AC, editors. Probiotic bacteria: fundamentals, therapy, and technological aspects. Singapore: Pan Stanford; 2014. 305 p.
176. Andrade E, Santos Pires AC dos, Soares M, Jan G, de Carvalho AF. Probiotics in Dairy Fermented Products. In: Rigobelo E, editor. Probiotics [Internet]. InTech; 2012 [cited 2017 May 8]. Available from: <http://www.intechopen.com/books/probiotics/probiotics-in-dairy-fermented-products>
177. Weichselbaum E. Probiotics and health: a review of the evidence. *Nutr Bull.* 2009; Dec 1; 34 (4): 340–73.
178. Lee B, Yin X, Griffey SM, Marco ML. Attenuation of colitis by *Lactobacillus casei* BL23 is dependent on the dairy delivery matrix. *Appl Environ Microbiol.* 2015; AEM. 01360-15.
179. Kort R, Westerik N, Mariela Serrano L, Douillard FP, Gottstein W, Mukisa IM, et al. A novel consortium of *Lactobacillus rhamnosus* and *Streptococcus thermophilus* for increased access to functional fermented foods. *Microb Cell Factories.* 2015; 14: 195.
180. Burgain J, Gaiani C, Linder M, Scher J. Encapsulation of probiotic living cells: From laboratory scale to industrial applications. *J Food Eng.* 2011; 104 (4): 467–83.
181. Chen M-J, Chen K-N. Applications of Probiotic Encapsulation in Dairy Products. In: Lakkis JM, editor. Encapsulation and Controlled Release Technologies in Food Systems [Internet]. Blackwell Publishing; 2007 [cited 2017 May 5]. p. 83–112. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/9780470277881.ch4/summary>
182. Dias DR, Botrel DA, Fernandes RVDB, Borges SV. Encapsulation as a tool for bioprocessing of functional foods. *Curr Opin Food Sci.* 2017; 13: 31–7.
183. Bosnea LA, Moschakis T, Biliaderis CG. Microencapsulated cells of *Lactobacillus paracasei* subsp. *paracasei* in biopolymer complex coacervates and their function in a yogurt matrix. *Food Funct.* 2017; 8 (2): 554–62.
184. Gomes da Cruz A, Alonso Buriti FC, Batista de Souza CH, Fonseca Faria JA, Isay Saad SM. Probiotic cheese: Health benefits, technological and stability aspects. *Trends Food Sci Technol.* 2009; 20 (8): 344–54.
185. Özer B, Kirmaci HA, Şenel E, Atamer M, Hayaloğlu A. Improving the viability of *Bifidobacterium bifidum* BB-12 and *Lactobacillus acidophilus* LA-5 in white-brined cheese by microencapsulation. *Int Dairy J.* 2009; 19 (1): 22–9.
186. Burns P, Patrignani F, Serrazanetti D, Vinderola GC, Reinheimer JA, Lanciotti R, et al. Probiotic Crescenza cheese containing *Lactobacillus casei* and *Lactobacillus acidophilus* manufactured with high-pressure homogenized milk. *J Dairy Sci.* 2008; 91 (2): 500–12.
187. Rabah H, Ménard O, ROSA DO CARMO FL, Plé C, Dupont D, Foligne B, et al. Is cheese a good delivery vehicle for the anti-inflammatory [*i*]Propionibacterium freudenreichii[*i*] probiotic? [Internet]. 2016 [cited 2017 May 5]. np. Available from: <https://hal.archives-ouvertes.fr/hal-01372132>
188. Gagnaire V, Jardin J, Rabah H, Briard-Bion V, Jan G. Emmental Cheese Environment Enhances *Propionibacterium freudenreichii* Stress Tolerance. *PloS One.* 2015;10 (8): e0135780.
189. Thierry.A, H. Falentin, S. M. Deutsch, and G. Jan. *Propionibacterium* spp. In: Encyclopedia of dairy sciences. Second Edition. Academic Press, San Diego (USA); 2011. p. 403–11. (F. P. a. M. P. Fuquay JW; vol. VOLUME 1).
190. Thierry A, Deutsch S-M, Falentin H, Dalmaso M, Cousin FJ, Jan G. New insights into physiology and metabolism of *Propionibacterium freudenreichii*. *Int J Food Microbiol.* 2011; 149 (1): 19–27.
191. McDowell A, Nagy I, Magyari M, Barnard E, Patrick S. The Opportunistic Pathogen *Propionibacterium acnes*: Insights into Typing, Human Disease, Clonal Diversification and CAMP Factor Evolution. Zhou D, editor. PLoS ONE. 2013; 8 (9): e70897.
192. Cousin FJ, Mater DDG, Foligne B, Jan G. Dairy propionibacteria as human probiotics: A review of recent evidence.

- Dairy Sci Technol [Internet]. 2010 [cited 2016 Nov 24]; Available from: <http://link.springer.com/10.1051/dst/2010032>
193. Klinman DM, Klaschik S, Tross D, Shiota H, Steinhagen F. FDA guidance on prophylactic DNA vaccines: analysis and recommendations. *Vaccine*. 2010; 28(16): 2801–5.
 194. EFSA Panel on Biological Hazards (BIOHAZ). Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update): QPS 2013 update. *EFSA J*. 2013; 11 (11): 3449.
 195. Falentin H, Deutsch S-M, Jan G, Loux V, Thierry A, Parayre S, et al. The Complete Genome of *Propionibacterium freudenreichii* CIRM-BIA1T, a Hardy Actinobacterium with Food and Probiotic Applications. Ahmed N, editor. *PLoS ONE*. 2010; 5 (7): e11748.
 196. Gagnaire V, Jardin J, Rabah H, Briard-Bion V, Jan G. Emmental Cheese Environment Enhances *Propionibacterium freudenreichii* Stress Tolerance. Nychas G-J, editor. *PLOS ONE*. 2015; 10 (8): e0135780.
 197. Zarate G. Dairy Propionibacteria: Less Conventional Probiotics to Improve the Human and Animal Health. In: Rigobelo E, editor. *Probiotic in Animals* [Internet]. InTech; 2012 [cited 2016 Oct 11]. Available from: <http://www.intechopen.com/books/probiotic-in-animals/dairy-propionibacteria-less-conventional-probiotics-to-improve-the-human-and-animal-health>
 198. Cousin FJ, Foligné B, Deutsch S-M, Massart S, Parayre S, Le Loir Y, et al. Assessment of the Probiotic Potential of a Dairy Product Fermented by *Propionibacterium freudenreichii* in Piglets. *J Agric Food Chem*. 2012; 60 (32): 7917–27.
 199. Hervé C, Fondrevez M, Chéron A, Barloy-Hubler F, Jan G. Transcarboxylase mRNA: A marker which evidences *P. freudenreichii* survival and metabolic activity during its transit in the human gut. *Int J Food Microbiol*. 2007; 113 (3): 303–14.
 200. Huang S, Cauty C, Dolivet A, Le Loir Y, Chen XD, Schuck P, et al. Double use of highly concentrated sweet whey to improve the biomass production and viability of spray-dried probiotic bacteria. *J Funct Foods*. 2016; 23: 453–63.
 201. Huang S, Rabah H, Jardin J, Briard-Bion V, Parayre S, Maillard M-B, et al. Hyperconcentrated Sweet Whey, a New Culture Medium That Enhances *Propionibacterium freudenreichii* Stress Tolerance. *Appl Environ Microbiol*. 2016; 82(15): 4641–51.
 202. Plé C, Richoux R, Jardin J, Nurdin M, Briard-Bion V, Parayre S, et al. Single-strain starter experimental cheese reveals anti-inflammatory effect of *Propionibacterium freudenreichii* CIRM BIA 129 in TNBS-colitis model. *J Funct Foods*. 2015; 18: 575–85.
 203. Plé C, Breton J, Richoux R, Nurdin M, Deutsch S-M, Falentin H, et al. Combining selected immunomodulatory *Propionibacterium freudenreichii* and *Lactobacillus delbrueckii* strains: Reverse engineering development of an anti-inflammatory cheese. *Mol Nutr Food Res*. 2015 Dec; n/a-n/a.
 204. Oksaharju A, Kooistra T, Kleemann R, van Duyvenvoorde W, Miettinen M, Lappalainen J, et al. Effects of probiotic *Lactobacillus rhamnosus* GG and *Propionibacterium freudenreichii* ssp. *shermanii* JS supplementation on intestinal and systemic markers of inflammation in ApoE*3Leiden mice consuming a high-fat diet. *Br J Nutr*. 2013; 110 (01): 77–85.
 205. Mitsuyama K, Masuda J, Yamasaki H, Kuwaki K, Kitazaki S, Koga H, et al. Treatment of Ulcerative Colitis with Milk Whey Culture with *Propionibacterium freudenreichii*. *J Intest Microbiol*. 2007;21 (2): 143–7.
 206. Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. *Nutrition*. 2006; 22 (1): 76–81.
 207. Kekkonen RA, Holma R, Hatakka K, Suomalainen T, Poussa T, Adlercreutz H, et al. A Probiotic Mixture Including Galactooligosaccharides Decreases Fecal α -Glucosidase Activity but Does Not Affect Serum Enterolactone Concentration in Men during a Two-Week Intervention. *J Nutr*. 2011;141 (5): 870–6.

208. Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, et al. The influence of *Lactobacillus rhamnosus* LC705 together with *Propionibacterium freudenreichii* ssp. *shermanii* JS on potentially carcinogenic bacterial activity in human colon. *Int J Food Microbiol.* 2008;128 (2): 406–10.
209. Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne-Muller G, et al. The probiotic *Propionibacterium freudenreichii* as a new adjuvant for TRAIL-based therapy in colorectal cancer. *Oncotarget.* 2016; 7 (6): 7161–78.
210. Cousin FJ, Foligné B, Deutsch S-M, Massart S, Parayre S, Le Loir Y, et al. Assessment of the Probiotic Potential of a Dairy Product Fermented by *Propionibacterium freudenreichii* in Piglets. *J Agric Food Chem.* 2012; 60 (32): 7917–27.
211. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel M-T, Corcos L, Jan G. Milk fermented by *Propionibacterium freudenreichii* induces apoptosis of HGT-1 human gastric cancer cells. *PloS One.* 2012; 7 (3): e31892.
212. Fagan RP, Fairweather NF. Biogenesis and functions of bacterial S-layers. *Nat Rev Microbiol.* 2014;12 (3): 211–22.
213. Lortal S, Rouault A, Cesselin B, Sleytr UB. Paracrystalline surface layers of dairy propionibacteria. *Appl Environ Microbiol.* 1993; 59 (8): 2369–74.
214. Le Maréchal C, Peton V, Plé C, Vroland C, Jardin J, Briard-Bion V, et al. Surface proteins of *Propionibacterium freudenreichii* are involved in its anti-inflammatory properties. *J Proteomics.* 2015; 113: 447–61.
215. Deutsch SM, Bivic PL, Herve C, Madec MN, LaPointe G, Jan G, et al. Correlation of the Capsular Phenotype in *Propionibacterium freudenreichii* with the Level of Expression of *gtf*, a Unique Polysaccharide Synthase-Encoding Gene. *Appl Environ Microbiol.* 2010; 76 (9): 2740–6.
216. Deutsch S-M, Parayre S, Bouchoux A, Guyomarc'h F, Dewulf J, Dols-Lafargue M, et al. Contribution of Surface -Glucan Polysaccharide to Physicochemical and Immunomodulatory Properties of *Propionibacterium freudenreichii*. *Appl Environ Microbiol.* 2012; 78(6): 1765–75.
217. Deutsch S-M, Mariadassou M, Nicolas P, Parayre S, Le Guellec R, Chuat V, et al. Identification of proteins involved in the anti-inflammatory properties of *Propionibacterium freudenreichii* by means of a multi-strain study. *Sci Rep.* 2017; 7: 46409.
218. Jan G, Belzacq A-S, Haouzi D, Rouault A, Métivier D, Kroemer G, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. *Cell Death Differ.* 2002; 9 (2): 179–88.
219. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel M-T, Corcos L, Jan G. Milk fermented by *Propionibacterium freudenreichii* induces apoptosis of HGT-1 human gastric cancer cells. *PloS One.* 2012; 7 (3): e31892.
220. Lan A, Bruneau A, Bensaada M, Philippe C, Bellaud P, Rabot S, et al. Increased induction of apoptosis by *Propionibacterium freudenreichii* TL133 in colonic mucosal crypts of human microbiota-associated rats treated with 1,2-dimethylhydrazine. *Br J Nutr.* 2008; 100 (06): 1251.
221. Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. *Apoptosis Int J Program Cell Death.* 2007; 12 (3): 573–91.
222. Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Moigne-Muller GL, et al. The probiotic *Propionibacterium freudenreichii* as a new adjuvant for TRAIL-based therapy in colorectal cancer. *Oncotarget.* 2016; 7 (6): 7161–78.
223. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The Role of Short-Chain Fatty Acids in Health and Disease. In: *Advances in Immunology* [Internet]. Elsevier; 2014 [cited 2017 Feb 1]. p. 91–119. Available from: <http://linkinghub.elsevier.com/retrieve/pii/B9780128001004000039>

224. Isawa K, Hojo K, Yoda N, Kamiyama T, Makino S, Saito M, et al. Isolation and Identification of a New Bifidogenic Growth Stimulator Produced by *Propionibacterium freudenreichii* ET-3. *Biosci Biotechnol Biochem*. 2002; 66 (3): 679–81.
225. Furuichi K, Hojo K, Katakura Y, Ninomiya K, Shioya S. Aerobic culture of *Propionibacterium freudenreichii* ET-3 can increase production ratio of 1,4-dihydroxy-2-naphthoic acid to menaquinone. *J Biosci Bioeng*. 2006; 101 (6): 464–70.
226. Kaneko T. A Novel Bifidogenic Growth Stimulator Produced by *Propionibacterium freudenreichii*. *Biosci Microflora*. 1999; 18 (2): 73–80.
227. Hojo K, Yoda N, Tsuchita H, Ohtsu T, Seki K, Taketomo N, et al. Effect of Ingested Culture of *Propionibacterium freudenreichii* ET-3 on Fecal Microflora and Stool Frequency in Healthy Females. *Biosci Microflora*. 2002; 21 (2): 115–20.
228. Isawa K, Hojo K, Yoda N, Kamiyama T, Makino S, Saito M, et al. Isolation and identification of a new bifidogenic growth stimulator produced by *Propionibacterium freudenreichii* ET-3. *Biosci Biotechnol Biochem*. 2002; 66 (3): 679–81.
229. Uchida M, Mogami O, Matsueda K. Characteristic of milk whey culture with *Propionibacterium freudenreichii* ET-3 and its application to the inflammatory bowel disease therapy. *Inflammopharmacology*. 2007; 15 (3): 105–8.
230. Okada Y. *Propionibacterium freudenreichii* component 1,4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. *Gut*. 2006; 55 (5): 681–8.
231. Fukumoto S, Toshimitsu T, Matsuoka S, Maruyama A, Oh-Oka K, Takamura T, et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. *Immunol Cell Biol*. 2014; 92 (5): 460–5.
232. Okada Y, Tsuzuki Y, Narimatsu K, Sato H, Ueda T, Hozumi H, et al. 1,4-Dihydroxy-2-naphthoic acid from *Propionibacterium freudenreichii* reduces inflammation in interleukin-10-deficient mice with colitis by suppressing macrophage-derived proinflammatory cytokines. *J Leukoc Biol*. 2013; 94 (3): 473–80.
233. De Prisco A, Mauriello G. Probiotication of foods: A focus on microencapsulation tool. *Trends Food Sci Technol*. 2016 Feb; 48: 27–39.
234. Irvani S, Korbekandi H, Mirmohammadi SV. Technology and potential applications of probiotic encapsulation in fermented milk products. *J Food Sci Technol*. 2015; 52 (8): 4679–96.
235. Abd El-Salam MH, El-Shibiny S. Preparation and properties of milk proteins-based encapsulated probiotics: a review. *Dairy Sci Technol*. 2015 Jul; 95 (4): 393–412.
236. Engineered Probiotics: Applications and Biological Containment. *Annu Rev Food Sci Technol*. 2017; 8 (1): 353–70.
237. Altieri C. Dairy propionibacteria as probiotics: recent evidences. *World J Microbiol Biotechnol*. 2016; 32 (10): 172.
238. Mitsuyama K, Masuda J, Yamasaki H, Kuwaki K, Kitazaki S, Koga H, et al. Treatment of Ulcerative Colitis with Milk Whey Culture with *Propionibacterium freudenreichii*. *J Intest Microbiol*. 2007; 21 (2): 143–7.
239. Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. *Nutr Burbank Los Angel Cty Calif*. 2006; 22 (1): 76–81.
240. Interest of *Propionibacterium Freudenreichii* for the Treatment of Mild to Moderate Ulcerative Colitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016 Oct 11]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02488954>